UPDATE 1-US FTC seeks more information on Novo Nordisk parent-Catalent deal

Reuters05-03

(Adds details from the filing in paragraphs 3,4)

May 3 (Reuters) - The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent .

The deal was announced in February and Novo Nordisk Foundation has since refiled its application to the U.S. FTC seeking regulatory approval for it.

Catalent in a regulatory filing on Friday said the companies were in the process of gathering information and documents to respond to FTC's request received on May 2 and intend to continue to cooperate with the regulator.

Catalent and Novo Holdings expect to close the deal towards the end of calendar year 2024.

Novo Holdings is the investment arm of Novo Nordisk's controlling shareholder, the Novo Nordisk Foundation.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432297132?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-03 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2432297132","market":"us","top_or_hot":-1,"title":"UPDATE 1-US FTC seeks more information on Novo Nordisk parent-Catalent deal","media":"Reuters","content":"<html><body><p>(Adds details from the filing in paragraphs 3,4)</p><p>      May 3 (Reuters) - The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's    parent to buy manufacturing subcontractor <a href=\"https://laohu8.com/S/CTLT\">Catalent</a>   .</p><p>   The deal was announced in February and Novo Nordisk Foundation has since refiled its application to the U.S. FTC seeking regulatory approval for it.</p><p>   Catalent in a regulatory filing on Friday said the companies were in the process of gathering information and documents to respond to FTC's request received on May 2 and intend to continue to cooperate with the regulator.</p><p>   Catalent and Novo Holdings expect to close the deal towards the end of calendar year 2024.</p><p>   Novo Holdings is the investment arm of Novo Nordisk's controlling shareholder, the Novo Nordisk Foundation.</p><p> (Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)</p><p>((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-US FTC seeks more information on Novo Nordisk parent-Catalent deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-US FTC seeks more information on Novo Nordisk parent-Catalent deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-03 20:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Adds details from the filing in paragraphs 3,4)      May 3 (Reuters) - The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's    parent to ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4530","symbol_name":"医药外包概念","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2432297132","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432297132","pubTimestamp":1714739818,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Adds details from the filing in paragraphs 3,4)      May 3 (Reuters) - The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's    parent to bu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4530":"医药外包概念","FTC":"First Trust Large Cap Growth Opp","BK4588":"碎股","BK4007":"制药","CTLT":"Catalent","BK4532":"文艺复兴科技持仓","NVO":"诺和诺德","BK4585":"ETF&股票定投概念"},"translate_title":"更新1-美国联邦贸易委员会寻求更多关于诺和诺德母公司——加泰罗尼亚交易的信息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTLT":1,"FTC":1,"NVO":1},"content_text":"(Adds details from the filing in paragraphs 3,4)      May 3 (Reuters) - The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's    parent to buy manufacturing subcontractor Catalent   .   The deal was announced in February and Novo Nordisk Foundation has since refiled its application to the U.S. FTC seeking regulatory approval for it.   Catalent in a regulatory filing on Friday said the companies were in the process of gathering information and documents to respond to FTC's request received on May 2 and intend to continue to cooperate with the regulator.   Catalent and Novo Holdings expect to close the deal towards the end of calendar year 2024.   Novo Holdings is the investment arm of Novo Nordisk's controlling shareholder, the Novo Nordisk Foundation. (Reporting by Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar)((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432297132"}